Federal plans to inspect a baby formula factory linked to the nationwide shortage were slowed by COVID-19, scheduling conflicts and other logistical problems, according to prepared testimony from the head of the Food and Drug Administration.
Abbott and the FDA have reached an agreement to reopen the plant next week, requiring the company to regularly undergo outside safety audits. But Califf's testimony suggests FDA efforts to reopen the plant were slowed by negotiations with Abbott, which had to be codified in a court agreement.
The FDA has also faced questions about its timeline for reviewing an October whistleblower complaint alleging numerous safety violations at Abbott’s plant, including employees falsifying records and failing to test formula. Califf's testimony details a two-month gap between when regulators received the report and when they actually interviewed the whistleblower.
Senior FDA officials did not receive copies of the whistleblower complaint until February due to “an isolated failure in FDA’s mailroom, likely due to COVID-19 staffing issues,” according to the prepared remarks.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Opinion | Why Is the FDA Seizing Baby Formula During a Baby Formula Shortage?From WSJopinion: The FDA’s actions have exacerbated the baby formula shortage problem they were trying to solve, write scottlincicome and emilyekins
Les mer »
FDA Chief to Detail Why Inspection of Baby Formula Plant Was DelayedThe head of the Food and Drug Administration is preparing to tell lawmakers about events that led to a months-long gap before inspecting the plant at the center of a nationwide baby formula shortage.
Les mer »
FDA chief to detail delays inspecting baby formula plantThe head of the Food and Drug Administration is preparing to tell lawmakers about events that led to a months-long gap before inspecting the plant at the center of a nationwide baby formula shortage.
Les mer »
U.S. FDA declines to authorize Verrica's viral skin disease treatmentThe U.S. Food and Drug Administration (FDA) declined to approve Verrica Pharmaceuticals Inc's drug for the treatment of a viral skin disease known as molluscum contagiosum, the company said on Tuesday.
Les mer »
Colorado Congresswoman Diana DeGette To Grill Baby Formula Manufacturers, FDA Over ShortageColorado Congresswoman Diana DeGette is leading a federal inquiry into the nation's baby formula shortage. DeGette is the Chair of the House Energy and Commerce Committee's Oversight and Investigations Subcommittee. She is also a new grandmother who understands the sense of panic and urgency gripping parents.
Les mer »
FDA head will explain holdups in inspection of baby formula facility amid shortageFDA chief Robert Califf will address concerns from Congress about the nationwide baby formula shortage as lawmakers investigate the details of what led to the shortage.
Les mer »